LIDDS.ST
LIDDS AB (publ) [LIDDS.ST] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
LIDDS.ST Stock Summary
In the News
LIDDS.ST Financial details
Company Rating
-
Market Cap
11.26M
Income
-40.26M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
2
Optionable
No
Shortable
Yes
Earnings
15 May 2024
P/E
-0.7
Forward P/E
-
PEG
0.19
P/S
-216.24
P/B
0.66
P/C
-
P/FCF
-0.72
Quick Ratio
4.43
Current Ratio
4.85
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.63
EPS next Y
-
EPS next Q
-
EPS this Y
-37%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
306.63%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-85%
ROE
-96%
ROC
-0.93%
Gross Margin
100%
Oper. Margin
27598%
Profit Margin
28138%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.103-1.395
52W High
-
52W Low
-
RSI
52
Rel Volume
0.1
Avg Volume
161.63K
Volume
15.79K
Perf Week
11.82%
Perf Month
-42.79%
Perf Quarter
-71.06%
Perf Half Y
-58.86%
-
-
-
-
Beta
0.237
-
-
Volatility
0%, 0.01%
Prev Close
0%
Price
0.0246
Change
0%
Company Profile
- Volume Average 161.63K
- Market Capitalization 11.26M
- Employee 2
- CEO Ms. Jenni Bjornulfson
- Headquarters Uppsala,SE
- IPO Date 2014-07-31
-
Website
https://www.liddspharma.com 
LIDDS AB (publ), a pharmaceutical company, develops and sells pharmaceutical products for cancer and other diseases in Sweden. It is developing various drugs, such as NZ-2HOF to treat prostate cancer; NZ-DTX to treat breast, prostate, head, neck, stomach, and lung cancer; NZ-DOX for the treatment of solid tumors; NZ-IO, an immunotherapy; NZ-STING for the treatment of immuno-oncology; and NZ-TLR9 for enhancing cancer immunotherapies. LIDDS AB (publ) has a collaboration agreement with PharmIdea SIA to focus on anti-cancer drugs and sterile formulations. The company is based in Uppsala, Sweden.
